Clinical Trials · NCT07295223
Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Instituto Mexicano del Seguro Social
- Enrollment
- 44
- Start date
- Dec 2025
- Locations
- 1 site, Mexico
- Primary endpoint
- Inflammatory markers (high-sensitivity PCR)